Celebrating Innovation and Collaboration at RSNA 2024
The Radiological Society of North America (RSNA) 2024 Annual Meeting once again set the stage for iCAD’s impactful presence, showcasing the latest advancements in breast imaging and artificial intelligence (AI). With over 40,000 attendees—an 18% increase from the previous year—and 715 exhibitors, the event underscored the rapidly growing focus on AI within the radiology field.
As a global leader in innovative cancer detection AI solutions, iCAD captured attention by highlighting the new FDA clearance of ProFound Detection Version 4.0, unveiling real-world clinical utility data, announcing transformative partnerships, delivering expert-led clinical AI presentations, and offering insights into future product innovations—all while celebrating meaningful milestones with customers and partners.
Photo by Padgett and Company Inc.
AI’s transformative impact on breast imaging was well highlighted at RSNA, including iCAD’s leadership position. From unveiling cutting-edge solutions and partnerships to engaging with imaging centers, this week was a celebration of innovation, collaboration, and commitment to improving patient care.
Here’s a look back at how we celebrated progress, partnerships, and the future of breast health care.
Clinical Expertise + iCAD in the Spotlight
Two expert-led clinical presentations demonstrated the life-changing potential of iCAD’s Breast Health AI solutions:
Dr. Chirag Parghi at the AI Showcase Theater:
Dr. Chirag Parghi, Chief Medical Officer at Solis Mammography captivated the audience with his presentation, “The Thin White Line: Which Calcifications Matter?” at the AI Showcase Theater.
Dr. Parghi highlighted how ProFound Detection Version 4.0 has achieved:
- 20% fewer marks related to vascular calcifications
- 51% fewer marks related to non-vascular calcifications
Chirag R. Parghi, MD
Chief Medical Officer at Solis Mammography
This significant reduction in unnecessary marks allows radiologists to focus on clinically relevant findings, improving diagnostic precision and accuracy. Through case studies, Dr. Parghi demonstrated how this advanced AI technology supports better differentiation and characterization of calcifications, empowering radiologists to make confident decisions while reducing unnecessary recalls.
Dr. Kathy Schilling’s Oral Abstract Presentation:
Dr. Kathy Schilling, Medical Director of the Christine E. Lynn Women’s Health & Wellness Institute, presented groundbreaking clinical research titled “The Real-World Effect of Artificial Intelligence on Histopathology and Stage in Breast Cancer Screening with Digital Breast Tomosynthesis.”
Dr. Schilling’s study of nine fellowship breast radiologists two-year use of ProFound AI Detection vs. the preceding two years when not using AI across a total of 103,182 mammograms showed2 incredible differences in cancer detection with AI:
- 23% increase in overall cancer detection rates (CDR)
- 4% rise in invasive cancer detection rates
- 2x increase in lobular cancer detection
- 32% boost in dense breast cancer detection
- 12% reduction in invasive cancer size
- 40% reduction in later stage (T2) tumors
These results were achieved without increasing recall rates, showcasing how ProFound AI detects more invasive cancers earlier while reducing unnecessary follow-ups.
Learn More: RSNA Presentations, Events, & Announcements
Collaboration Through Panels and Demos
Patients win when we work together, and you could see that collaboration showcasing the power of partnerships through dynamic panels and live demonstrations:
Breast Health AI Innovation Station: Powered by iCAD, Densitas, and CancerIQ
Attendees engaged in hands-on demos of ProFound AI, which seamlessly integrates with CancerIQ’s lifetime risk evaluation and Densitas’ AI-driven image quality tools.
Blackford Partner Panel: Enhancing Breast Cancer Care with AI.
Dr. Mark Traill, Breast Radiologist at the University of Michigan Health-West, joined the Blackford Partner Panel to highlight how AI is transforming breast imaging workflows. The discussion focused on how iCAD’s solutions enhance detection accuracy, streamline workflows, and elevate patient care, while also improving MQSA quality scores to help radiologists meet quality standards with confidence. Dr. Traill shared real-world insights, emphasizing how these advancements are driving measurable quality improvements across breast health care.
CARPL.ai Partner Panel: Breast AI
During the CARPL.ai Partner Panel, Peter Graham, SVP of Commercial at iCAD, participated in a dynamic discussion about the evolving landscape of mammography AI. The panel explored key market trends, adoption opportunities, and emerging AI solutions that are shaping the future of breast cancer care. Peter emphasized how iCAD’s AI-powered innovations are setting new standards in mammography by enhancing precision and efficiency. These advancements enable radiologists to make more confident, data-driven decisions, ultimately improving breast cancer detection and patient outcomes.
GE HealthCare Expert Corner
iCAD joined GE HealthCare at their booth daily to showcase the seamless integration of ProFound AI Breast Health Suite with GE mammography systems. These discussions highlighted how combining AI with advanced imaging systems enhances diagnostic precision and efficiency.
Explore GE HealthCare and iCAD Clinical White Paper: Real-Word Results comparing DBT screenings with and without ProFound AI
Better Together: iCAD’s ProFound Partnerships
ProFound Detection Version 4.0: FDA-Cleared AI for Better Outcomes
The unveiling of ProFound Detection Version 4.0 marks a pivotal moment in breast cancer detection. This next-generation AI solution is FDA-cleared and delivers1:
- 22% overall improvement in detecting aggressive cancers,
- 18% improvement in cases with no marks, and
- incorporates prior exams into its analysis for deeper clinical insights.
By reducing false positives and optimizing radiologist workflows, ProFound Detection V4 sets a new benchmark for AI-powered digital breast tomosynthesis (DBT).
Blog: ProFound Detection Version 4.0: The Next Generation in Early Breast Cancer Detection
Expanding Our Reach: iCAD and Cascaid Health Partnership
Announcing ProFound Health
At RSNA 2024, iCAD announced a new partnership with Cascaid Health, unveiling ProFound Health, a virtual care model powered by Cascaid. Scheduled for beta launch in Q1 2025, this collaboration offers virtual second reads of mammograms using ProFound AI to democratize access to cutting-edge breast cancer detection.
Learn More: ProFound Health Partnership with Cascaid Health
Looking Ahead: What’s Next in Breast Health AI
RSNA 2024 was a celebration of iCAD’s commitment to advancing breast cancer detection through innovation and collaboration. As we look to 2025, the integration of AI in breast health care will continue to improve precision, accuracy, and early detection, bringing us closer to a world where cancer can’t hide.
It’s About Time. To elevate breast health with precision and clarity.
Empower your patients with iCAD’s AI-powered solutions, delivering faster, more precise insights to help you deliver exceptional care today—and tomorrow.
Learn how iCAD’s AI solutions can elevate your approach to breast health.
Thank you to everyone who joined us at RSNA. Together, we’re shaping the future of breast health care.
Don’t miss the opportunity to improve diagnostic precision! Schedule your consultation today.
References:
1. Compared to prior Version 3.0. ProFound Detection not available in all geographies.
2. Schilling, K. et al. Oral Abstract Research Presented at RSNA 2024; Chicago, Illinois.